OBJECTIVE: RENASICA III is a prospective, multicenter registry on acute coronary syndromes (ACS). The main objective will be to identify the outcome in tertiary and community hospitals and perform strategies to improve quality of care in Mexico. METHODS: RENASICA III will enroll 8000 patients in public health and private hospitals. The registry began in November 2012 with a planned recruitment during 12 months and a 1-year follow-up. The study population will comprise a consecutive, prospective cohort of patients >18 years with ACS final diagnosis and evidence of ischemic heart disease. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, RENASICA III emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.
OBJECTIVE: RENASICA III is a prospective, multicenter registry on acute coronary syndromes (ACS). The main objective will be to identify the outcome in tertiary and community hospitals and perform strategies to improve quality of care in Mexico. METHODS: RENASICA III will enroll 8000 patients in public health and private hospitals. The registry began in November 2012 with a planned recruitment during 12 months and a 1-year follow-up. The study population will comprise a consecutive, prospective cohort of patients >18 years with ACS final diagnosis and evidence of ischemic heart disease. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, RENASICA III emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.
Authors: Carmen Arroyo-Quiroz; Martin O'Flaherty; Maria Guzman-Castillo; Simon Capewell; Eduardo Chuquiure-Valenzuela; Carlos Jerjes-Sanchez; Tonatiuh Barrientos-Gutierrez Journal: PLoS One Date: 2020-12-03 Impact factor: 3.240
Authors: Grecia I M Raymundo-Martínez; Diego Araiza-Garaygordobil; Rodrigo Gopar-Nieto; Arnoldo E Loáisiga-Sáenz; Luis A Baeza-Herrera; Ricardo Pohls-Vázquez; Laura V Torres-Araujo; Manuel Martínez-Ramos Méndez; Arturo I Alonso; Itzel V Delgado-Cruz; Diestefano E Ronquillo-Ramírez; Alexandra Arias-Mendoza Journal: Arch Cardiol Mex Date: 2020-11-11